Evidence map›Paper›PMID 37311602›Full record

Trial reportBMJ open diabetes research & care2023

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.

David M Charytan, Kenneth W Mahaffey, Meg J Jardine, Christopher P Cannon, Bruce Neal, Hiddo J Lambers Heerspink, Rajiv Agarwal, George L Bakris, Dick de Zeeuw, Adeera Levin and 10 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open diabetes research & care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 6 countries.

David M CharytanUnited States, NYU, New York, New York, USA.
Kenneth W MahaffeyDepartment of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Meg J JardineThe University of Sydney, Sydney, New South Wales, Australia.
Christopher P CannonBaim Institute for Clinical Research, Boston, Massachusetts, USA.
Bruce NealThe University of Sydney, Sydney, New South Wales, Australia.
Hiddo J Lambers HeerspinkChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Rajiv AgarwalVA Medical Center, Bedford, Massachusetts, USA.
George L BakrisUChicago Medicine, Chicago, Illinois, USA.
Dick de ZeeuwClinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
Adeera LevinNephrology, St. Paul's Hospital, Newtown, New South Wales, Australia.
Carol PollockMedicine, The University of Sydney, Sydney, New South Wales, Australia.
Hong ZhangRenal Division of Peking University First Hospital, Beijing, China.
Bernard ZinmanUniversity of Toronto, Toronto, Ontario, Canada.
Norman RosenthalJanssen Research & Development LLC, Raritan, New Jersey, USA.
Vlado PerkovicGeorge Institute for Global Health, Sydney, New South Wales, Australia.
Gian Luca Di TannaGeorge Institute for Global Health, Sydney, New South Wales, Australia.
Jie YuGeorge Institute for Global Health, Sydney, New South Wales, Australia.
Kris RogersGeorge Institute for Global Health, Sydney, New South Wales, Australia.
Clare ArnottThe George Institute for Global Health, Newtown, New South Wales, Australia.
David C WheelerDepartment of Renal Medicine, UCL, London, UK d.wheeler@ucl.ac.uk.ORCID 0000-0003-0745-3478
The George Institute for Global Health · AUThe University of Sydney · AUBaim Institute for Clinical Research · USBedford VA Research Corporation · USChildren's Hospital of Philadelphia · USJanssen (United States) · USPeking University · CNRoyal North Shore Hospital · AUStanford University · USUniversity College of Osteopathy · GBUniversity Medical Center Groningen · NLUniversity of Chicago · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRelationships between glycemic-lowering effects of sodium glucose co-transporter 2 inhibitors and impact on kidney and cardiovascular outcomes are uncertain. RESEARCH DESIGN AND

methodsWe analyzed 4395 individuals with prebaseline and postbaseline hemoglobin A1c (HbA1c) randomized to canagliflozin (n=2193) or placebo (n=2202) in The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation trial. Effects on HbA1c were assessed using mixed models. Mediation of treatment effects by achieved glycemic control was analyzed using proportional hazards regression with and without adjustment for achieved HbA1c. End points included combined kidney or cardiovascular death, end-stage kidney disease or doubling of serum creatinine (primary trial outcome), and individual end point components.

resultsHbA1c lowering was modified by baseline estimated glomerular filtration rate (eGFR). For baseline eGFR 60-90, 45-59, and 30-44 mL/min/1.73 m

conclusionsThe glycemic effects of canagliflozin are attenuated at lower eGFR but effects on kidney and cardiac end points are preserved. Non-glycemic effects may be primarily responsible for the kidney and cardioprotective benefits of canagliflozin.22.

Indexed as

Kidney Failure, ChronicSodium-Glucose Transporter 2 InhibitorsCanagliflozinGlucoseGlycated HemoglobinHumansKidneyCanagliflozinGlucoseGlycated HemoglobinSodium-Glucose Transporter 2 Inhibitorsdiabetes mellitus, type 2kidney failure, chronic

Identifiers

PMID37311602
PMCPMC10277062
OpenAlexW4380536921

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.